Electrocore LLC - Asset Resilience Ratio
Electrocore LLC (ECOR) has an Asset Resilience Ratio of 25.69% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Electrocore LLC to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Electrocore LLC's Asset Resilience Ratio has changed over time. See how leveraged is Electrocore LLC's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Electrocore LLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Electrocore LLC market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.98 Million | 25.69% |
| Total Liquid Assets | $3.98 Million | 25.69% |
Asset Resilience Insights
- Very High Liquidity: Electrocore LLC maintains exceptional liquid asset reserves at 25.69% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Electrocore LLC Industry Peers by Asset Resilience Ratio
Compare Electrocore LLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Electrocore LLC (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Electrocore LLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.51% | $4.58 Million | $18.67 Million | -17.10pp |
| 2024-12-31 | 41.61% | $8.52 Million | $20.47 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $16.10 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $42.83 Million | -- |
| 2020-12-31 | 58.34% | $18.39 Million | $31.52 Million | +28.74pp |
| 2019-12-31 | 29.60% | $10.50 Million | $35.46 Million | -53.34pp |
| 2018-12-31 | 82.94% | $60.96 Million | $73.50 Million | +21.89pp |
| 2017-12-31 | 61.05% | $23.95 Million | $39.23 Million | -- |
About Electrocore LLC
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic… Read more